Characteristics of the 26 study subjects with ET
| Sex (M/F) | 12/14 |
| Median age, y (range) | 60.3 (31-77) |
| Median duration since diagnosis, mo (range) | 34.2 (2-84) |
| Subjects with venous thrombosis | 3/26 (12%) |
| Subjects with arterial thrombosis | 5/26 (19%) |
| Subjects with abnormal bleeding | 2/26 (8%) |
| Median platelet count (range) | 397 × 109/L (198-567) |
| Jak2 V617F (+ve/−ve) | 20/6 |
| No treatment | 2/26 (8%) |
| Aspirin alone | 12/26 (46%) |
| Aspirin + hydroxycarbamide | 12/26 (46%) |
| Sex (M/F) | 12/14 |
| Median age, y (range) | 60.3 (31-77) |
| Median duration since diagnosis, mo (range) | 34.2 (2-84) |
| Subjects with venous thrombosis | 3/26 (12%) |
| Subjects with arterial thrombosis | 5/26 (19%) |
| Subjects with abnormal bleeding | 2/26 (8%) |
| Median platelet count (range) | 397 × 109/L (198-567) |
| Jak2 V617F (+ve/−ve) | 20/6 |
| No treatment | 2/26 (8%) |
| Aspirin alone | 12/26 (46%) |
| Aspirin + hydroxycarbamide | 12/26 (46%) |